Update on chemoinfusion and chemo-embolization treatments;Update chemoperfusion und -embolisation

Radiologe

Volumn 47, Issue 12, 2007, Pages 1097-1108

  Lubienski, A ^a,d   Simon, M ^a   Lubienski, K ^a   Gellissen, J ^a   Hoffmann, R T ^b   Jakobs, T F ^b   Helmberger, T ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c KLINIKUM BOGENHAUSEN   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Hepatocellular carcinoma; Liver metastases; Minimally invasive therapy; Transarterial chemoembolization; Transarterial chemoinfusion therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOSTATIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IODINATED POPPYSEED OIL; IRINOTECAN; MITOMYCIN; MITOMYCIN C; OXALIPLATIN; PIRARUBICIN;

CANCER CHEMOTHERAPY; CHEMOEMBOLIZATION; CHEMOINFUSION; COLORECTAL TUMOR METASTASIS; HUMAN; INFUSION; LIVER CELL CARCINOMA; LIVER TUMOR; METASTASIS; REVIEW; TRANSARTERIAL EMOBOLIZATION; TRANSARTERIAL INFUSION CHEMOTHERAPY;

ANGIOGRAPHY; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETERS, INDWELLING; CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; RADIOLOGY, INTERVENTIONAL; TREATMENT OUTCOME;

EID: 36849025611     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-007-1587-4     Document Type: Review

References (73)

1. Jemal A, Murray T, Ward E et al. (2005) Cancer statistics. CA Cancer J Clin 55: 10-30
2. Choti MA, Bulkley GB (1999) Management of hepatic metastases. Liver Transpl Surg 5: 65-80
3. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917
4. Jonker DJ, Maroun JA, Kocha W (2000) Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 82: 1789-1794
5. Lubienski A, Eckey T, Lubienski K et al. (2007) Interventionelle Verfahren zur Therapie von Lebertumoren. Viszeralchirurgie 42: 249-258
6. Yamagami T, Kato T, Iida S et al. (2004) Value of transcatheter arterial embolization with coils and n-butyl cyanoacrylate for long-term hepatic arterial infusion chemotherapy. Radiology 230: 792-802
7. Lai Y-C, Shih C-Y, Jeng C-M et al. (2003) Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with tumor thrombosis of the portal vein. World J Gastroenterol 9: 2666-2670
8. Tajima T, Yoshimitsu K, Kuroiwa T et al. (2005) Percutaneous femoral catheter placement for long-term chemotherapy infusion: preliminary technical results. Am J Roentgenol 184: 906-914
9. Yamagami T, Kato T, Tanaka O et al. (2005) Radiofrequency ablation therapy of remnant colorectal liver metastases after a course of hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 16: 549-554
10. Yamagami T, Iida S, Kato T et al. (2002) Using n-butyl cyanoacrylate and the fixed-catheter-tip technique in percutaneous implantation of a port-catheter system in patients undergoing repeated hepatic arterial chemotherapy. Am J Roentgenol 179: 1611-1617
11. Morise Z, Sugioka A, Kato R et al. (2006) Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases. J Gastrointest Surg 10: 249-258
12. Sumie S, Yamashita F, Ando E et al. (2003) Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. Am J Roentgenol 181: 1327-1334
13. Kemeny N, Garay CA, Gurtler J et al. (2004) Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 22: 4753-4761
14. Folprecht G, Lutz MP, Schöffski P et al. (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17: 450-456
15. Sangro B, Rios R, Bilbao I et al. (2002) Efficacy and toxicity of intra-arterial cisplatin and etoposide for advanced hepatocellular carcinoma. Oncology 62: 293-298
16. Arai Y, Inaba Y, Takeuchi Y, Ariyoshi Y (1997) Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother Pharmacol 40: 526-530
17. Meta-Analysis Group in Cancer (1996) Reappraisal of HAI in the treatment of nonresectable liver metastases from colorectal carcinoma. J Natl Cancer Inst 88: 252-258
18. Del Freo A, Fiorentini G, Sanguinetti F et al. (2006) Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-flourouracil in pre-treated patients with liver metastases from colorectal cancer. In Vivo 20: 743-746
19. Kemeny NE, Niedzwiecki D, Hollis DR et al. (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24: 1395-1403
20. Kemeny N, Jarnagin W, Paty P et al. (2004) Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectalcancer. J Clin Oncol 23: 4888-4896
21. Ducreux M, Ychou M, Laplanche A et al. (2005) Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases:a trial of the Gastrointestinal Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23: 4881-4887
22. Pohlen U, Rieger H, Mansmann U et al. (2006) Hepatic arterial infusion (HAI). Comparison of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres versus 5-fluorouracil and folinic acid in patienst with non-resectable colorectal liver metastases. Anticancer Res 26: 3957-3964
23. Van Hazel G, Blackwell A, Anderson J et al. (2004) Randomised phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88: 78-85
24. Zhu AX, Fuchs CS, Clark JW et al. (2006) A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist 11: 87-88
25. Boige V, Taieb J, Hebbar M et al. (2006) Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 42: 456-459
26. Hamada A, Yamakado K, Nakatsuka A et al. (2004) Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors. J Vasc Interv Radiol 15: 835-841
27. Lerose R, Molinari R, Rocchi E et al. (2001) Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer 37: 239-245
28. Giannelli G, Pierri F, Trerotoli P et al. (2002) Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival: a retropsective clinical study of 150 cases. Hepatol Res 24: 50
29. Iwamiya T, Sawada S, Ohta Y (1994) Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 33 [suppl]: S134-138
30. Yamashita Y, Takahashi M, Koga Y et al. (1991) Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 67: 385-391
31. Gornet JM, Azoulay D, Duclos-Vallee JC, Goldwasser F et al. (2000) Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11. Anticancer Drugs 11: 649-652
32. Lim TY, Cheong JY, Cho SW et al. (2006) Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis. Korean J Hepatol 12: 65-73
33. Allen PJ, Nissan A, Picon AI et al. (2005) Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 201: 57-65
34. Ricke J, Hildebrandt B, Miersch A et al. (2004) Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events. J Vasc Interv Radiol 15: 825-833
35. Venturini M, Angeli E, Salvioni M et al. (2004) Complications after percutaneous transaxillary implantation of a catheter for intraarterial chemotherapy of liver tumors: clinical management in 204 patients. Am J Roentgenol 182: 1417-1426
36. Marelli L, Stigliano R, Triantos C et al. (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30: 6-25
37. Chung JW, Park JH, Im JG et al. (1993) Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 187: 689-693
38. Kobayashi S, Narimatsu Y, Ogawa K et al. (1992) Transcatheter hepatic arterial chemoembolization using epirubicin-lipiodol: experimental and pharmacological evaluation. Cancer Chemother Pharmacol 31 [suppl]: S45-50
39. Johnson PJ, Kalayci C, Dobbs N et al. (1991) Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 13: 120-127
40. Favoulet P, Cercueil JP, Faure P et al. (2001) Increased cytotoxicity and stability of lipiodol-pirarubicin emulsion compared to classical doxorubicin-lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma. Anticancer Drugs 12: 801-806
41. Llado L, Virgili J, Figueras J et al. (2000) A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 88: 50-57
42. Brown DB, Pilgram TK, Darcy MD et al. (2005) Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 16: 1661-1666
43. Seki H, Kimura M, Yoshimura N et al. (1998) Development of extrahepatic arterial blood supply to the liver during hepatic arterial infusion chemotherapy. Eur Radiol 8: 1613-1618
44. Lewis AL, Gonzalez MV, Lloyd AW et al. (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17: 335-342
45. Varela M, Real MI, Burrel M et al. (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46: 474-481
46. Hong K, Khwaja A, Liapi E et al. (2006) New intra-arterial drug delivery system fort the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12: 2563-2567
47. Lewis AL, Gonzalez MV, Lloyd AW et al. (2006) Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 17: 1335-1343
48. Huppert PE, Lauchart W, Duda SH et al. (2004) Chemoembolization of hepatocellular carcinomas: which factors determine therapeutic response and survival? Fortschr Röntgenstr 176: 375-385
49. Ho AS, Picus J, Darcy MD et al. (2007) Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. Am J Roentgenol 188: 1201-1207
50. Horiguchi Y, Itoh M, Takagawa H et al. (1992) Assessment of chemoembolization therapy for primary liver cancer using a stabilized adriamycin-lipiodol suspension. Cancer Chemother Pharmacol 31 [suppl]: S60-64
51. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332: 1256-1261
52. Bruix J, Llovet JM, Castells A et al. (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27: 1578-1583
53. Lo CM, Ngan H, Tso WK et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171
54. Llovet JM, Real MI, Montana X et al. (2002) Barcelona liver cancer group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoima: a randomized controlled trial. Lancet 359: 1734-1739
55. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442
56. Takayasu K, Arii S, Ikai I et al. (2006) Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131: 461-469
57. Wong LL, Tanaka K, Lau L, Komura S (2004) Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transplant 18: 227-234
58. Graziadei IW, Sandmueller H, Waldenberger P et al. (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9: 557-563
59. Kamel IR, Bluemke DA, Ramsey D et al. (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. Am J Roentgenol 181: 708-710
60. Otto G, Herber S, Heise M et al. (2006) Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12: 1260-1267
61. Mazzaferro V, Regalia E, Doci R et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699
62. Gupta S, Johnson MM, Murthy R et al. (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104: 1590-1602
63. Ruutiainen AT, Soulen MC, Tuite CM et al. (2007) Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 18: 847-855
64. Patel K, Sullivan K, Berd D et al. (2005) Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 15: 297-304
65. Li XP, Meng ZQ, Guo WJ, Li J (2005) Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol 11: 3782-3787
66. Herber S, Otto G, Schneider J et al. (2007) Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol May 17; [Epub ahead of print]
67. Voigt W, Behrmann C, Schlueter A et al. (2002) A new chemoembolization protocol in refractory liver metastasis of colorectal cancer - a feasibility study. Onkologie 25: 158-164
68. Wasser K, Giebel F, Fischbach R et al. (2005) Transarterial chemoembolization of liver metastases of colorectal carcinoma using degradable starch microspheres (spherex): personal investigations and review of the literature. Radiologe 45: 633-643
69. Vogl TJ, Zangos S, Balzer JO et al. (2002) Transarterial chemoembolization of liver metastases: Indication, technique, results. Rofo 174: 675-683
70. Chan AO, Yuen MF, Hui CK et al. (2003) A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94: 1747-1752
71. Tarazov PG, Polysalov VN, Prozorovskij KV et al. (2000) Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol 41: 156-160
72. Song SY, Chung YW, Han JK et al. (2001) Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 12: 313-320
73. Wang MQ, Shao RH, Ye HY et al. (2005) Investigation of bile duct injury after transcatheter arterial chemoembolization. Zhonghua Zhong Liu Za Zhi 27: 609-612